Joshua  Silverman net worth and biography

Joshua Silverman Biography and Net Worth

Joshua Silverman has served as a member of the Board of Directors since September 6, 2018 and currently serves as lead independent director and Chairman of the Board. Mr. Silverman currently serves as the managing member of Parkfield Funding LLC. Mr. Silverman was the co-founder, and a principal and managing partner of Iroquois Capital Management, LLC (“Iroquois”), an investment advisory firm. Since its inception in 2003 until July 2016, Mr. Silverman served as co-chief investment officer of Iroquois. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co-chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the United States. Mr. Silverman currently serves as a director of AYRO, Inc., Protagenic Therapeutics, and Neurotrope, Inc., all of which are public companies. He previously served as a director of National Holdings Corporation from July 2014 through August 2016 and as a director of Marker Therapeutics, Inc. from August 2016 until October 2018. Mr. Silverman received his B.A. from Lehigh University in 1992.

What is Joshua Silverman's net worth?

The estimated net worth of Joshua Silverman is at least $68,000.00 as of October 15th, 2020. Mr. Silverman owns 50,000 shares of MyMD Pharmaceuticals stock worth more than $68,000 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Silverman may own. Learn More about Joshua Silverman's net worth.

How do I contact Joshua Silverman?

The corporate mailing address for Mr. Silverman and other MyMD Pharmaceuticals executives is 855 N. WOLFE STREET, BALTIMORE MD, 21205. MyMD Pharmaceuticals can also be reached via phone at 856-848-8698 and via email at [email protected]. Learn More on Joshua Silverman's contact information.

Has Joshua Silverman been buying or selling shares of MyMD Pharmaceuticals?

Joshua Silverman has not been actively trading shares of MyMD Pharmaceuticals during the last ninety days. Most recently, on Friday, November 26th, Joshua Silverman bought 166 shares of MyMD Pharmaceuticals stock. The stock was acquired at an average cost of $226.50 per share, with a total value of $37,599.00. Learn More on Joshua Silverman's trading history.

Who are MyMD Pharmaceuticals' active insiders?

MyMD Pharmaceuticals' insider roster includes Paul Rivard (EVP), and Joshua Silverman (Director). Learn More on MyMD Pharmaceuticals' active insiders.

Joshua Silverman Insider Trading History at MyMD Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/26/2021Buy166$226.50$37,599.00View SEC Filing Icon  
11/24/2021Buy333$196.80$65,534.40View SEC Filing Icon  
See Full Table

Joshua Silverman Buying and Selling Activity at MyMD Pharmaceuticals

This chart shows Joshua Silverman's buying and selling at MyMD Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MyMD Pharmaceuticals Company Overview

MyMD Pharmaceuticals logo
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Read More

Today's Range

Now: $1.36
Low: $1.35
High: $1.50

50 Day Range

MA: $1.40
Low: $1.10
High: $1.82

2 Week Range

Now: $1.36
Low: $1.75
High: $63.90

Volume

128,784 shs

Average Volume

134,123 shs

Market Capitalization

$3.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15